The global molecular imaging market is expected to witness robust growth through 2027, primarily driven by an increased demand for advanced integrated molecular imaging devices such as PET-CT and PET-MR from hospitals and diagnostics imaging centers, according to a recent report from Future Market Insights.
The firm projects the market to register a compound annual growth rate of 7.5% during the forecast period, valuing $6.44 billion by 2027.
On the basis of modality type, single photon emission, computed tomography (SPECT) accounted for 23.3% market share in 2016, and is expected to decrease to 22.7% by 2027. On the other hand, the PET-CT molecular imaging segment is expected to witness a significant rise in revenue share over the forecast period, owing to growing awareness about the advantages of PET-CT integrated devices compared to standalone molecular imaging devices.
Segmented by end user, hospitals dominated the global molecular imaging market in revenue in 2016, and the trend is projected to continue throughout the forecast period. The hospitals segment is expected to be the most lucrative among all end users, and is expected to grab a 58% revenue share in 2027.
By application, in terms of value, oncology is the largest segment and is likely to be valued $2.39 billion in 2027.
The Asia/Pacific Excluding Japan market segment’s revenue is expected to expand at a significant CAGR of 8.6% in terms of value over the forecast period. The hospitals and diagnostics imaging centers in this region are expected to witness comparatively significant growth due to a heightened demand of advanced molecular imaging and developing medical infrastructure in the region.
